Literature DB >> 24106013

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Steven M Kornblau1, Aileen C Cohen, David Soper, Ying-Wen Huang, Alessandra Cesano.   

Abstract

BACKGROUND: Single Cell Network Profiling (SCNP) is a multiparametric flow cytometry-based assay that quantifiably and simultaneously measures changes in intracellular signaling proteins in response to in vitro extracellular modulators at the single cell level. Myelodysplastic syndrome (MDS) is a heterogeneous clonal disorder of hematopoietic stem cells that occurs in elderly subjects and is characterized by dysplasia and ineffective hematopoiesis. The functional responsiveness of MDS bone marrow (BM) hematopoietic cells, including functionally distinct myeloid and erythroid precursor subsets, to hematopoietic growth factors (HGF) and the relationship of modulated signaling to disease characteristics is poorly understood.
METHODS: SCNP was used first to examine the effects of age on erythropoietin (EPO) and granulocyte colony stimulating factor (GCSF)-induced signaling in myeloid, nucleated red blood cells (nRBC), and CD34 expressing cell subsets in healthy BM (n = 15). SCNP was then used to map functional signaling profiles in low risk (LR) MDS (n = 7) for comparison to signaling in samples from healthy donors and to probe signaling associations within clinically defined subgroups.
RESULTS: In healthy BM samples, signaling responses to HGF were quite homogeneous (i.e., tightly regulated) with age-dependent effects observed in response to EPO but not to GCSF. Despite the relatively small number of samples assayed in the study, LR MDS could be classified into distinct subgroups based on both cell subset frequency and signaling profiles.
CONCLUSIONS: As a correlate of underlying genetic abnormalities, signal transduction analyses may provide a functional and potentially clinically relevant classification of MDS. Further evaluation in a larger cohort is warranted.
© 2013 Clinical Cytometry Society.

Entities:  

Keywords:  EPO; GCSF; MDS; SCNP; age-related bone marrow cell signaling; signaling

Mesh:

Substances:

Year:  2013        PMID: 24106013      PMCID: PMC4922007          DOI: 10.1002/cyto.b.21125

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  34 in total

1.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.

Authors:  F Damm; F Thol; O Kosmider; S Kade; P Löffeld; F Dreyfus; A Stamatoullas-Bastard; A Tanguy-Schmidt; O Beyne-Rauzy; S de Botton; A Guerci-Bresler; G Göhring; B Schlegelberger; A Ganser; O A Bernard; M Fontenay; M Heuser
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

2.  Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Authors:  Steven M Kornblau; Mark D Minden; David B Rosen; Santosh Putta; Aileen Cohen; Todd Covey; David C Spellmeyer; Wendy J Fantl; Urte Gayko; Alessandra Cesano
Journal:  Clin Cancer Res       Date:  2010-06-04       Impact factor: 12.531

3.  Multi-platform, multi-site instrumentation and reagent standardization.

Authors:  N Purvis; G Stelzer
Journal:  Cytometry       Date:  1998-10-01

Review 4.  The lower risk MDS patient at risk of rapid progression.

Authors:  Moshe Mittelman; Howard S Oster; Michael Hoffman; Drorit Neumann
Journal:  Leuk Res       Date:  2010-06-22       Impact factor: 3.156

5.  Serum erythropoietin concentrations in patients with myelodysplastic syndromes.

Authors:  C Aul; M Arning; V Runde; W Schneider
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

6.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

7.  Plasma erythropoietin levels in the oldest old.

Authors:  C G Musso; C A F Musso; H Joseph; R De Miguel; P Rendo; E Gonzalez; L Algranati; E dos Ramos Farias
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 8.  Anemia in the elderly: current understanding and emerging concepts.

Authors:  Richard Eisenstaedt; Brenda W J H Penninx; Richard C Woodman
Journal:  Blood Rev       Date:  2006-02-10       Impact factor: 8.250

9.  Evaluation of the effect of age on hematopoiesis in the C57BL/6 mouse.

Authors:  L H Williams; K B Udupa; D A Lipshitz
Journal:  Exp Hematol       Date:  1986-10       Impact factor: 3.084

10.  Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.

Authors:  Alessandra Cesano; Santosh Putta; David B Rosen; Aileen C Cohen; Urte Gayko; Kavita Mathi; John Woronicz; Rachael E Hawtin; Larry Cripe; Zhuoxin Sun; Martin S Tallman; Elisabeth Paietta
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

View more
  3 in total

1.  The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Authors:  Astrid Olsnes Kittang; Kristoffer Sand; Annette Katharina Brenner; Kristin Paulsen Rye; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

2.  Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.

Authors:  Stefan G C Mestrum; Norbert C J de Wit; Roosmarie J M Drent; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Cytometry B Clin Cytom       Date:  2020-08-28       Impact factor: 3.058

3.  Immune monitoring technology primer: Single Cell Network Profiling (SCNP).

Authors:  Rachael E Hawtin; Alessandra Cesano
Journal:  J Immunother Cancer       Date:  2015-08-18       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.